A clinical trial to test if NU100 is safe and can treat patient with r
A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis
What was tested
Treatment tested
- NU100
Compared with
- Interferon beta-1b
Interferon alpha/beta receptor agonist
What it measured
Main measures
- Cohort 1: new CALs after 4 months of treatment based on the MRI outcomes obtained at Months 2, 3, and 4
MRI lesions
Other measures (1)
- Incidence of annualized relapse rates
Relapses
Loading reviews and guidelines…
History
- In scope changed from true to false
Started
Nov 2011
Assembled by software from public sources.